{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:24:32Z","timestamp":1790796272331,"version":"4.1.0"},"reference-count":185,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 GM122733-03A1"],"award-info":[{"award-number":["P30 GM122733-03A1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000070","name":"National Institute of Biomedical Imaging and Bioengineering","doi-asserted-by":"publisher","award":["R21EB031454-01A1"],"award-info":[{"award-number":["R21EB031454-01A1"]}],"id":[{"id":"10.13039\/100000070","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.addr.2023.114824","type":"journal-article","created":{"date-parts":[[2023,4,15]],"date-time":"2023-04-15T10:50:11Z","timestamp":1681555811000},"page":"114824","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Current and future directions of drug delivery for the treatment of mental illnesses"],"prefix":"10.1016","volume":"197","author":[{"given":"Parker R.","family":"Brewster","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saif","family":"Mohammad Ishraq Bari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn M.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6005-1243","authenticated-orcid":false,"given":"Thomas A.","family":"Werfel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.addr.2023.114824_b0005","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/s41386-021-01109-z","article-title":"The prefrontal cortex, pathological anxiety, and anxiety disorders","volume":"47","author":"Kenwood","year":"2022","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.addr.2023.114824_b0010","article-title":"The Diagnosis and Treatment of Anxiety Disorders","author":"Str\u00f6hle","year":"2018","journal-title":"Dtsch Arztebl Int"},{"key":"10.1016\/j.addr.2023.114824_b0015","doi-asserted-by":"crossref","first-page":"107","DOI":"10.31887\/DCNS.2017.19.2\/macrocq","article-title":"The history of generalized anxiety disorder as a diagnostic category","volume":"19","author":"Crocq","year":"2017","journal-title":"Dialogues Clin Neurosci"},{"key":"10.1016\/j.addr.2023.114824_b0020","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1080\/14656566.2018.1491966","article-title":"Pharmacotherapy for generalized anxiety disorder in adult and pediatric patients: an evidence-based treatment review","volume":"19","author":"Strawn","year":"2018","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.addr.2023.114824_b0025","doi-asserted-by":"crossref","first-page":"e100161","DOI":"10.1136\/gpsych-2019-100161","article-title":"Towards a precision psychiatry approach to anxiety disorders with ecological momentary assessment: the example of panic disorder","volume":"33","author":"Robinaugh","year":"2020","journal-title":"Gen Psychiatr"},{"key":"10.1016\/j.addr.2023.114824_b0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.janxdis.2022.102546","article-title":"Social anxiety disorder in adolescents: Prevalence and subtypes in the Young-HUNT3 study","volume":"87","author":"Aune","year":"2022","journal-title":"J Anxiety Disord"},{"key":"10.1016\/j.addr.2023.114824_b0035","first-page":"678","article-title":"Specific phobias. Lancet","volume":"5","author":"Eaton","year":"2018","journal-title":"Psychiatry"},{"key":"10.1016\/j.addr.2023.114824_b0040","doi-asserted-by":"crossref","first-page":"127","DOI":"10.31887\/DCNS.2017.19.2\/dstein","article-title":"Epidemiology of anxiety disorders: from surveys to nosology and back","volume":"19","author":"Stein","year":"2017","journal-title":"Dialogues Clin Neurosci"},{"key":"10.1016\/j.addr.2023.114824_b0045","doi-asserted-by":"crossref","first-page":"351","DOI":"10.31887\/DCNS.2016.18.4\/fthibaut","article-title":"The role of sex and gender in neuropsychiatric disorders","volume":"18","author":"Thibaut","year":"2016","journal-title":"Dialogues Clin Neurosci"},{"key":"10.1016\/j.addr.2023.114824_b0050","doi-asserted-by":"crossref","unstructured":"Bandelow, B. Current and Novel Psychopharmacological Drugs for Anxiety Disorders. in 347-365 (2020).","DOI":"10.1007\/978-981-32-9705-0_19"},{"key":"10.1016\/j.addr.2023.114824_b0055","doi-asserted-by":"crossref","first-page":"87","DOI":"10.31887\/DCNS.2017.19.2\/fthibaut","article-title":"Anxiety disorders: a review of current literature","volume":"19","author":"Thibaut","year":"2017","journal-title":"Dialogues Clin Neurosci"},{"key":"10.1016\/j.addr.2023.114824_b0060","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s11019-015-9636-7","article-title":"Fundamental challenges for autism research: the science-practice gap, demarcating autism and the unsuccessful search for the neurobiological basis of autism","volume":"18","author":"Verhoeff","year":"2015","journal-title":"Med Health Care Philos"},{"key":"10.1016\/j.addr.2023.114824_b0065","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2019.00526","article-title":"State of the Field: Differentiating Intellectual Disability From Autism Spectrum Disorder","volume":"10","author":"Thurm","year":"2019","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.addr.2023.114824_b0070","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.rasd.2017.03.004","article-title":"Behavioral comparisons in Autism Spectrum Disorder and Developmental Coordination Disorder: A systematic literature review","volume":"38","author":"Ca\u00e7ola","year":"2017","journal-title":"Res Autism Spectr Disord"},{"key":"10.1016\/j.addr.2023.114824_b0075","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1007\/s10803-016-2814-5","article-title":"Social (Pragmatic) Communication Disorder and Its Relation to the Autism Spectrum: Dilemmas Arising From the DSM-5 Classification","volume":"46","author":"Brukner-Wertman","year":"2016","journal-title":"J Autism Dev Disord"},{"key":"10.1016\/j.addr.2023.114824_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.rasd.2019.101468","article-title":"Identifying comorbid ADHD in autism: Attending to the inattentive presentation","volume":"69","author":"Rau","year":"2020","journal-title":"Res Autism Spectr Disord"},{"key":"10.1016\/j.addr.2023.114824_b0085","doi-asserted-by":"crossref","unstructured":"Martino, D., Ganos, C. & Pringsheim, T. M. Tourette Syndrome and Chronic Tic Disorders: The Clinical Spectrum Beyond Tics. in 1461-1490 (2017).","DOI":"10.1016\/bs.irn.2017.05.006"},{"key":"10.1016\/j.addr.2023.114824_b0090","article-title":"Early diagnosis of autism and impact on prognosis: a narrative review","volume":"33","author":"Fernell Eriksson & Gillberg, C.","year":"2013","journal-title":"Clin Epidemiol"},{"key":"10.1016\/j.addr.2023.114824_b0095","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/BF02098832","article-title":"The definition and prevalence of autism: A review","volume":"2","author":"Wing","year":"1993","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"10.1016\/j.addr.2023.114824_b0100","doi-asserted-by":"crossref","first-page":"5308","DOI":"10.1007\/s10803-021-05377-y","article-title":"Defining in Detail and Evaluating Reliability of DSM-5 Criteria for Autism Spectrum Disorder (ASD) Among Children","volume":"52","author":"Rice","year":"2022","journal-title":"J Autism Dev Disord"},{"key":"10.1016\/j.addr.2023.114824_b0105","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s13052-022-01310-w","article-title":"The global prevalence of autism spectrum disorder: a comprehensive systematic review and meta-analysis","volume":"48","author":"Salari","year":"2022","journal-title":"Ital J Pediatr"},{"key":"10.1016\/j.addr.2023.114824_b0110","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/j.1469-7610.1989.tb00275.x","article-title":"Asperger Syndrome?Some Epidemiological Considerations: A Research Note","volume":"30","author":"Gillberg","year":"1989","journal-title":"Journal of Child Psychology and Psychiatry"},{"issue":"Suppl 1","key":"10.1016\/j.addr.2023.114824_b0115","first-page":"3","article-title":"Epidemiology of autistic disorder and other pervasive developmental disorders","volume":"66","author":"Fombonne","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.addr.2023.114824_b0120","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1177\/1087054709332458","article-title":"Girls With Social and\/or Attention Deficits: A Descriptive Study of 100 Clinic Attenders","volume":"14","author":"Kopp","year":"2010","journal-title":"J Atten Disord"},{"key":"10.1016\/j.addr.2023.114824_b0125","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1056\/NEJMra012941","article-title":"Post-Traumatic Stress Disorder","volume":"346","author":"Yehuda","year":"2002","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.addr.2023.114824_b0130","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/nrn3339","article-title":"Biological studies of post-traumatic stress disorder","volume":"13","author":"Pitman","year":"2012","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.addr.2023.114824_b0135","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1056\/NEJMra1612499","article-title":"Post-Traumatic Stress Disorder","volume":"376","author":"Shalev","year":"2017","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.addr.2023.114824_b0140","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1002\/wps.20656","article-title":"Post-traumatic stress disorder: a state-of-the-art review of evidence and challenges","volume":"18","author":"Bryant","year":"2019","journal-title":"World Psychiatry"},{"key":"10.1016\/j.addr.2023.114824_b0145","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41593-020-00748-7","article-title":"Transcriptomic organization of the human brain in post-traumatic stress disorder","volume":"24","author":"Girgenti","year":"2021","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.addr.2023.114824_b0150","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1080\/13854046.2020.1811894","article-title":"Post-traumatic stress disorder: A differential diagnostic consideration for COVID-19 survivors","volume":"34","author":"Kaseda","year":"2020","journal-title":"Clin Neuropsychol"},{"key":"10.1016\/j.addr.2023.114824_b0155","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1093\/ijnp\/pyz064","article-title":"The CINP Guidelines on the Definition and Evidence-Based Interventions for Treatment-Resistant Bipolar Disorder","volume":"23","author":"Fountoulakis","year":"2020","journal-title":"International Journal of Neuropsychopharmacology"},{"key":"10.1016\/j.addr.2023.114824_b0160","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/s41380-019-0634-7","article-title":"The genetics of bipolar disorder","volume":"25","author":"Gordovez","year":"2020","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.addr.2023.114824_b0165","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1177\/2045125318769235","article-title":"Epidemiology and risk factors for bipolar disorder","volume":"8","author":"Rowland","year":"2018","journal-title":"Ther Adv Psychopharmacol"},{"key":"10.1016\/j.addr.2023.114824_b0170","series-title":"Diagnosis and Boundaries of Bipolar Disorders. in Bipolar Disorder 1\u201395","author":"Akiskal Classification","year":"2002"},{"key":"10.1016\/j.addr.2023.114824_b0175","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1056\/NEJMra1906193","article-title":"Bipolar Disorder","volume":"383","author":"Carvalho","year":"2020","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.addr.2023.114824_b0180","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.neubiorev.2019.09.025","article-title":"Shared pathways for neuroprogression and somatoprogression in neuropsychiatric disorders","volume":"107","author":"Morris","year":"2019","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.addr.2023.114824_b0185","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1093\/ijnp\/pyz034","article-title":"Maintenance Pharmacological Treatment of Juvenile Bipolar Disorder: Review and Meta-Analyses","volume":"22","author":"Yee","year":"2019","journal-title":"International Journal of Neuropsychopharmacology"},{"key":"10.1016\/j.addr.2023.114824_b0190","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.genhosppsych.2019.03.006","article-title":"Unrecognized bipolar disorder in patients with depression managed in primary care: A systematic review and meta-analysis","volume":"58","author":"Daveney","year":"2019","journal-title":"Gen Hosp Psychiatry"},{"key":"10.1016\/j.addr.2023.114824_b0195","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/nature09552","article-title":"Rethinking schizophrenia","volume":"468","author":"Insel","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.addr.2023.114824_b0200","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1001\/jamapsychiatry.2019.3360","article-title":"Schizophrenia\u2014An Overview","volume":"77","author":"McCutcheon","year":"2020","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.addr.2023.114824_b0205","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1176\/appi.ajp.2008.08050714","article-title":"Paul Eugen Bleuler and the Birth of Schizophrenia (1908)","volume":"165","author":"Fusar-Poli","year":"2008","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.addr.2023.114824_b0210","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0920-9964(97)00043-1","article-title":"Positive and negative symptom behaviors and caregiver burden in the relatives of persons with schizophrenia","volume":"26","author":"Provencher","year":"1997","journal-title":"Schizophr Res"},{"key":"10.1016\/j.addr.2023.114824_b0215","doi-asserted-by":"crossref","first-page":"e141","DOI":"10.1371\/journal.pmed.0020141","article-title":"A Systematic Review of the Prevalence of Schizophrenia","volume":"2","author":"Saha","year":"2005","journal-title":"PLoS Med"},{"key":"10.1016\/j.addr.2023.114824_b0220","doi-asserted-by":"crossref","first-page":"764","DOI":"10.4088\/JCP.15m10278","article-title":"The Economic Burden of Schizophrenia in the United States in 2013","volume":"77","author":"Cloutier","year":"2016","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.addr.2023.114824_b0225","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S2215-0366(17)30078-0","article-title":"Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis","volume":"4","author":"Hjorth\u00f8j","year":"2017","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.addr.2023.114824_b0230","doi-asserted-by":"crossref","first-page":"361","DOI":"10.3390\/medicina55070361","article-title":"Suicide in Schizophrenia: An Educational Overview","volume":"55","author":"Sher","year":"2019","journal-title":"Medicina (B Aires)"},{"key":"10.1016\/j.addr.2023.114824_b0235","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/j.hlc.2020.07.003","article-title":"Sudden Cardiac Death in Schizophrenia: A Review","volume":"29","author":"Vohra","year":"2020","journal-title":"Heart Lung Circ"},{"key":"10.1016\/j.addr.2023.114824_b0240","doi-asserted-by":"crossref","first-page":"16065","DOI":"10.1038\/nrdp.2016.65","article-title":"Major depressive disorder","volume":"2","author":"Otte","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.addr.2023.114824_b0245","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1001\/archgenpsychiatry.2009.36","article-title":"Cross-National Associations Between Gender and Mental Disorders in the World Health Organization World Mental Health Surveys","volume":"66","author":"Seedat","year":"2009","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.addr.2023.114824_b0250","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S0140-6736(15)60692-4","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990\u20132013: a systematic analysis for the Global Burden of Disease Study 2013","volume":"386","author":"Vos","year":"2015","journal-title":"The Lancet"},{"key":"10.1016\/j.addr.2023.114824_b0255","doi-asserted-by":"crossref","DOI":"10.1177\/1753944719851950","article-title":"Inflammation, depression and cardiovascular disease in women: the role of the immune system across critical reproductive events","volume":"13","author":"Mattina","year":"2019","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"10.1016\/j.addr.2023.114824_b0260","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.bbi.2020.02.005","article-title":"Depression and suicidality: A link to premature T helper cell aging and increased Th17 cells","volume":"87","author":"Schiweck","year":"2020","journal-title":"Brain Behav Immun"},{"key":"10.1016\/j.addr.2023.114824_b0265","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.neuron.2014.01.027","article-title":"The Genetics of Major Depression","volume":"81","author":"Flint","year":"2014","journal-title":"Neuron"},{"key":"10.1016\/j.addr.2023.114824_b0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.chiabu.2019.104082","article-title":"The association between five forms of child maltreatment and depressive and anxiety disorders: A systematic review and meta-analysis","volume":"96","author":"Gardner","year":"2019","journal-title":"Child Abuse Negl"},{"key":"10.1016\/j.addr.2023.114824_b0275","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1080\/15622975.2017.1289240","article-title":"Neurobiology of depression: A neurodevelopmental approach","volume":"19","author":"Lima-Ojeda","year":"2018","journal-title":"The World Journal of Biological Psychiatry"},{"key":"10.1016\/j.addr.2023.114824_b0280","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s40273-021-01019-4","article-title":"The Economic Burden of Adults with Major Depressive Disorder in the United States (2010 and 2018)","volume":"39","author":"Greenberg","year":"2021","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.addr.2023.114824_b0285","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1177\/070674371005500303","article-title":"The Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Trial: A Review","volume":"55","author":"Sinyor","year":"2010","journal-title":"The Canadian Journal of Psychiatry"},{"key":"10.1016\/j.addr.2023.114824_b0290","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1001\/jamapsychiatry.2016.2586","article-title":"Toward an Evidence-Based, Operational Definition of Treatment-Resistant Depression","volume":"74","author":"Conway","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.addr.2023.114824_b0295","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S0006-3223(03)00231-2","article-title":"Diagnosis and definition of treatment-resistant depression","volume":"53","author":"Fava","year":"2003","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.addr.2023.114824_b0300","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.jad.2008.01.006","article-title":"Serious life events among resistant and non-resistant MDD patients","volume":"110","author":"Amital","year":"2008","journal-title":"J Affect Disord"},{"key":"10.1016\/j.addr.2023.114824_b0305","doi-asserted-by":"crossref","first-page":"24","DOI":"10.4088\/JCP.17m11725","article-title":"Direct and Indirect Cost Burden and Change of Employment Status in Treatment-Resistant Depression","volume":"79","author":"Amos","year":"2018","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.addr.2023.114824_b0310","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/2045-5380-2-14","article-title":"Somatic therapies for treatment-resistant depression: ECT, TMS, VNS","volume":"2","author":"Cusin","year":"2012","journal-title":"DBS. Biol Mood Anxiety Disord"},{"key":"10.1016\/j.addr.2023.114824_b0315","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.12998\/wjcc.v7.i17.2420","article-title":"Attention deficit hyperactivity disorder and comorbidity: A review of literature","volume":"7","author":"Gnanavel","year":"2019","journal-title":"World J Clin Cases"},{"key":"10.1016\/j.addr.2023.114824_b0320","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s00406-021-01250-2","article-title":"ASD symptoms in adults with ADHD: a preliminary study using the ADOS-2","volume":"272","author":"Hayashi","year":"2022","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"10.1016\/j.addr.2023.114824_b0325","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/s41380-018-0070-0","article-title":"Genetics of attention deficit hyperactivity disorder","volume":"24","author":"Faraone","year":"2019","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.addr.2023.114824_b0330","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s11920-022-01324-5","article-title":"Koyuncu, A., Ayan, T., Ince Guliyev, E., Erbilgin, S. & Deveci, E. ADHD and Anxiety Disorder Comorbidity in Children and Adults","volume":"24","author":"Diagnostic and Therapeutic Challenges","year":"2022","journal-title":"Curr Psychiatry Rep"},{"key":"10.1016\/j.addr.2023.114824_b0335","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.neubiorev.2021.01.017","article-title":"Comorbidity of ADHD and adult bipolar disorder: A systematic review and meta-analysis","volume":"124","author":"Schiweck","year":"2021","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.addr.2023.114824_b0340","article-title":"Annual Research Review: Perspectives on progress in <scp>ADHD<\/scp> science - from characterization to cause","author":"Sonuga-Barke","year":"2022","journal-title":"Journal of Child Psychology and Psychiatry"},{"key":"10.1016\/j.addr.2023.114824_b0345","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/j.jaac.2021.01.019","article-title":"Systematic Review: How the Attention-Deficit\/Hyperactivity Disorder Polygenic Risk Score Adds to Our Understanding of ADHD and Associated Traits","volume":"60","author":"Ronald","year":"2021","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.addr.2023.114824_b0350","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/acps.12845","article-title":"Gender differences in psychiatric comorbidity: a population-based study of 40 000 adults with attention deficit hyperactivity disorder","volume":"137","author":"Solberg","year":"2018","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.addr.2023.114824_b0355","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajp.2022.103205","article-title":"Gender-based differences in prevalence and effects of ADHD in adults: A systematic review","volume":"75","author":"Faheem","year":"2022","journal-title":"Asian J Psychiatr"},{"key":"10.1016\/j.addr.2023.114824_b0360","doi-asserted-by":"crossref","DOI":"10.1016\/j.abrep.2018.100158","article-title":"Associations between attention deficit hyperactivity and internet gaming disorder symptoms: Is there consistency across types of symptoms, gender and countries?","volume":"9","author":"Stavropoulos","year":"2019","journal-title":"Addictive Behaviors Reports"},{"key":"10.1016\/j.addr.2023.114824_b0365","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/YIC.0000000000000078","article-title":"Efficacy of treatments for anxiety disorders","volume":"30","author":"Bandelow","year":"2015","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.addr.2023.114824_b0370","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2020.595584","article-title":"Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options","volume":"11","author":"Garakani","year":"2020","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.addr.2023.114824_b0375","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jaac.2020.03.007","article-title":"Meta-analysis: Pharmacologic Treatment of Restricted and Repetitive Behaviors in Autism Spectrum Disorders","volume":"60","author":"Zhou","year":"2021","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.addr.2023.114824_b0380","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.biopsych.2021.10.008","article-title":"Mining Clinical Data for Novel Posttraumatic Stress Disorder Medications","volume":"91","author":"Shiner","year":"2022","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.addr.2023.114824_b0385","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1111\/pcn.12852","article-title":"Current understanding of bipolar disorder: Toward integration of biological basis and treatment strategies","volume":"73","author":"Kato","year":"2019","journal-title":"Psychiatry Clin Neurosci"},{"key":"10.1016\/j.addr.2023.114824_b0390","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1055\/a-1854-0185","article-title":"Pharmacological Treatment of Early-Onset Schizophrenia: A Critical Review, Evidence-Based Clinical Guidance and Unmet Needs","volume":"55","author":"Lopez-Morinigo","year":"2022","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.addr.2023.114824_b0395","doi-asserted-by":"crossref","first-page":"9350","DOI":"10.12998\/wjcc.v9.i31.9350","article-title":"Major depressive disorder: Validated treatments and future challenges","volume":"9","author":"Karrouri","year":"2021","journal-title":"World J Clin Cases"},{"key":"10.1016\/j.addr.2023.114824_b0400","doi-asserted-by":"crossref","first-page":"36","DOI":"10.21037\/tp.2017.08.02","article-title":"Pharmacologic management of attention deficit hyperactivity disorder in children and adolescents: a review for practitioners","volume":"7","author":"Brown","year":"2018","journal-title":"Transl Pediatr"},{"key":"10.1016\/j.addr.2023.114824_b0405","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1177\/0004867415616695","article-title":"Mortality associated with anxiolytic and hypnotic drugs\u2014A systematic review and meta-analysis","volume":"50","author":"Parsaik","year":"2016","journal-title":"Australian & New Zealand Journal of Psychiatry"},{"key":"10.1016\/j.addr.2023.114824_b0410","doi-asserted-by":"crossref","first-page":"185","DOI":"10.18773\/austprescr.2020.054","article-title":"The role of drugs in the treatment of autism","volume":"43","author":"Turner","year":"2020","journal-title":"Aust Prescr"},{"key":"10.1016\/j.addr.2023.114824_b0415","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1007\/s40489-019-00189-4","article-title":"Primary Care Physicians\u2019 Knowledge of Autism and Evidence-Based Interventions for Autism: A Systematic Review","volume":"7","author":"McCormack","year":"2020","journal-title":"Rev J Autism Dev Disord"},{"key":"10.1016\/j.addr.2023.114824_b0420","doi-asserted-by":"crossref","first-page":"4370","DOI":"10.1007\/s10803-021-05237-9","article-title":"Decades of Progress in the Psychopharmacology of Autism Spectrum Disorder","volume":"51","author":"Henneberry","year":"2021","journal-title":"J Autism Dev Disord"},{"key":"10.1016\/j.addr.2023.114824_b0425","doi-asserted-by":"crossref","DOI":"10.1016\/j.rasd.2020.101520","article-title":"Olanzapine, risperidone, and aripiprazole use in children and adolescents with Autism Spectrum Disorders","volume":"72","author":"Tural Hesapcioglu","year":"2020","journal-title":"Res Autism Spectr Disord"},{"key":"10.1016\/j.addr.2023.114824_b0430","doi-asserted-by":"crossref","first-page":"15057","DOI":"10.1038\/nrdp.2015.57","article-title":"Post-traumatic stress disorder","volume":"1","author":"Yehuda","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.addr.2023.114824_b0435","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1192\/bjp.bp.114.148551","article-title":"Pharmacotherapy for post-traumatic stress disorder: Systematic review and meta-analysis","volume":"206","author":"Hoskins","year":"2015","journal-title":"British Journal of Psychiatry"},{"key":"10.1016\/j.addr.2023.114824_b0440","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/s41398-019-0673-5","article-title":"Pharmacological prevention and early treatment of post-traumatic stress disorder and acute stress disorder: a systematic review and meta-analysis","volume":"9","author":"Astill Wright","year":"2019","journal-title":"Transl Psychiatry"},{"key":"10.1016\/j.addr.2023.114824_b0445","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1017\/S0033291714001305","article-title":"A network meta-analysis on comparative efficacy and all-cause discontinuation of antimanic treatments in acute bipolar mania","volume":"45","author":"Yildiz","year":"2015","journal-title":"Psychol Med"},{"key":"10.1016\/j.addr.2023.114824_b0450","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s40263-015-0235-1","article-title":"Pharmacotherapy of Acute Mania: Monotherapy or Combination Therapy with Mood Stabilizers and Antipsychotics?","volume":"29","author":"Grande","year":"2015","journal-title":"CNS Drugs"},{"key":"10.1016\/j.addr.2023.114824_b0455","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/bdi.12373","article-title":"Anti-inflammatory agents in the treatment of bipolar depression: a systematic review and meta-analysis","volume":"18","author":"Rosenblat","year":"2016","journal-title":"Bipolar Disord"},{"key":"10.1016\/j.addr.2023.114824_b0460","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/S2215-0366(16)30264-4","article-title":"Safety and efficacy of adjunctive second-generation antidepressant therapy with a mood stabiliser or an atypical antipsychotic in acute bipolar depression: a systematic review and meta-analysis of randomised placebo-controlled trials","volume":"3","author":"McGirr","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.addr.2023.114824_b0465","article-title":"Transdermal delivery of second-generation antipsychotics for management of schizophrenia; disease overview, conventional and nanobased drug delivery systems","volume":"61","author":"El-Tokhy","year":"2021","journal-title":"J Drug Deliv Sci Technol"},{"key":"10.1016\/j.addr.2023.114824_b0470","doi-asserted-by":"crossref","first-page":"5294","DOI":"10.3390\/molecules25225294","article-title":"Nano Carrier Drug Delivery Systems for the Treatment of Neuropsychiatric Disorders: Advantages and Limitations","volume":"25","author":"Zorkina","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.addr.2023.114824_b0475","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41380-020-0843-0","article-title":"Discontinuation of antidepressants after remission with antidepressant medication in major depressive disorder: a systematic review and meta-analysis","volume":"26","author":"Kato","year":"2021","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.addr.2023.114824_b0480","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/PSY.0000000000000678","article-title":"Major Depressive Disorder in Medical Illness: A Review of Assessment, Prevalence, and Treatment Options","volume":"81","author":"Thom","year":"2019","journal-title":"Psychosom Med"},{"key":"10.1016\/j.addr.2023.114824_b0485","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctim.2021.102770","article-title":"Folate as adjunct therapy to SSRI\/SNRI for major depressive disorder: Systematic review & meta-analysis","volume":"61","author":"Altaf","year":"2021","journal-title":"Complement Ther Med"},{"key":"10.1016\/j.addr.2023.114824_b0490","doi-asserted-by":"crossref","first-page":"3542","DOI":"10.1038\/s41598-020-60527-z","article-title":"Primary functional brain connections associated with melancholic major depressive disorder and modulation by antidepressants","volume":"10","author":"Ichikawa","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.addr.2023.114824_b0495","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.20m13699","article-title":"The Prevalence and National Burden of Treatment-Resistant Depression and Major Depressive Disorder in the United States","volume":"82","author":"Zhdanava","year":"2021","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.addr.2023.114824_b0500","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","article-title":"Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study","volume":"3","author":"Carhart-Harris","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.addr.2023.114824_b0505","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00213-017-4771-x","article-title":"Psilocybin with psychological support for treatment-resistant depression: six-month follow-up","volume":"235","author":"Carhart-Harris","year":"2018","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.addr.2023.114824_b0510","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1177\/0269881117725915","article-title":"Serotonin and brain function: a tale of two receptors","volume":"31","author":"Carhart-Harris","year":"2017","journal-title":"Journal of Psychopharmacology"},{"key":"10.1016\/j.addr.2023.114824_b0515","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1038\/npp.2017.84","article-title":"The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future","volume":"42","author":"Carhart-Harris","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.addr.2023.114824_b0520","doi-asserted-by":"crossref","first-page":"46421","DOI":"10.1038\/srep46421","article-title":"Increased spontaneous MEG signal diversity for psychoactive doses of ketamine","volume":"7","author":"Schartner","year":"2017","journal-title":"LSD and psilocybin. Sci Rep"},{"key":"10.1016\/j.addr.2023.114824_b0525","doi-asserted-by":"crossref","first-page":"13187","DOI":"10.1038\/s41598-017-13282-7","article-title":"Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms","volume":"7","author":"Carhart-Harris","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.addr.2023.114824_b0530","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/s41591-022-01744-z","article-title":"Increased global integration in the brain after psilocybin therapy for depression","volume":"28","author":"Daws","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.addr.2023.114824_b0535","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1021\/acschemneuro.9b00493","article-title":"Psychedelics, but Not Ketamine, Produce Persistent Antidepressant-like Effects in a Rodent Experimental System for the Study of Depression","volume":"11","author":"Hibicke","year":"2020","journal-title":"ACS Chem Neurosci"},{"key":"10.1016\/j.addr.2023.114824_b0540","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S2215-0366(18)30269-4","article-title":"Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis","volume":"5","author":"Cortese","year":"2018","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.addr.2023.114824_b0545","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1176\/appi.ajp.2021.21010032","article-title":"Variable Patterns of Remission From ADHD in the Multimodal Treatment Study of ADHD","volume":"179","author":"Sibley","year":"2022","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.addr.2023.114824_b0550","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD010840.pub2","article-title":"Cognitive-behavioural interventions for attention deficit hyperactivity disorder (ADHD) in adults","volume":"2018","author":"Lopez","year":"2018","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1016\/j.addr.2023.114824_b0555","doi-asserted-by":"crossref","first-page":"e0240584","DOI":"10.1371\/journal.pone.0240584","article-title":"Pharmacologic treatment of attention deficit hyperactivity disorder in adults: A systematic review and network meta-analysis","volume":"15","author":"Elliott","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.addr.2023.114824_b0560","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1111\/jcpp.13305","article-title":"Practitioner Review: Pharmacological treatment of attention-deficit\/hyperactivity disorder symptoms in children and youth with autism spectrum disorder: a systematic review and meta-analysis","volume":"62","author":"Rodrigues","year":"2021","journal-title":"Journal of Child Psychology and Psychiatry"},{"key":"10.1016\/j.addr.2023.114824_b0565","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.chc.2022.03.008","article-title":"Updates in Pharmacologic Strategies in Adult Attention-Deficit\/Hyperactivity Disorder","volume":"31","author":"Anbarasan","year":"2022","journal-title":"Child Adolesc Psychiatr Clin N Am"},{"key":"10.1016\/j.addr.2023.114824_b0570","doi-asserted-by":"crossref","DOI":"10.1016\/j.neubiorev.2022.104575","article-title":"Sensitization-based risk for substance abuse in vulnerable individuals with ADHD: Review and re-examination of evidence","volume":"135","author":"Ivanov","year":"2022","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.addr.2023.114824_b0575","doi-asserted-by":"crossref","first-page":"705","DOI":"10.9758\/cpn.2021.19.4.705","article-title":"Combined Medication with Stimulants and Non-stimulants for Attention-deficit\/hyperactivity Disorder","volume":"19","author":"Bahn","year":"2021","journal-title":"Clinical Psychopharmacology and Neuroscience"},{"key":"10.1016\/j.addr.2023.114824_b0580","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jad.2020.01.075","article-title":"Suicidal ideation and attempts in the United States of America among stimulant-treated, non-stimulant-treated, and untreated patients with a diagnosis of attention-deficit\/hyperactivity disorder","volume":"266","author":"Siffel","year":"2020","journal-title":"J Affect Disord"},{"key":"10.1016\/j.addr.2023.114824_b0585","doi-asserted-by":"crossref","unstructured":"Prausnitz, M. R. & Langer, R. Transdermal drug delivery. Nature Biotechnology vol. 26 1261-1268 Preprint at Doi: 10.1038\/nbt.1504 (2008).","DOI":"10.1038\/nbt.1504"},{"key":"10.1016\/j.addr.2023.114824_b0590","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1176\/appi.ajp.159.11.1869","article-title":"Transdermal selegiline in major depression: A double-blind, placebo-controlled, parallel-group study in outpatients","volume":"159","author":"Bodkin","year":"2002","journal-title":"American Journal of Psychiatry"},{"key":"10.1016\/j.addr.2023.114824_b0595","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jad.2019.10.050","article-title":"Rapid and sustained improvement in treatment-refractory depression through use of acute intravenous ketamine and concurrent transdermal selegiline: A case series","volume":"262","author":"Lu","year":"2020","journal-title":"J Affect Disord"},{"key":"10.1016\/j.addr.2023.114824_b0600","unstructured":"Zarzar, M. et al. Transdermal selegiline Transdermal Selegiline: The New Generation of Monoamine Oxidase Inhibitors."},{"key":"10.1016\/j.addr.2023.114824_b0605","unstructured":"25981_treatment-social-phobia-antidepressants."},{"key":"10.1016\/j.addr.2023.114824_b0610","doi-asserted-by":"crossref","unstructured":"Joseph McClernon, F., Berry Hiott, F., Westman, E. C., Rose, J. E. & Levin, E. D. Transdermal nicotine attenuates depression symptoms in nonsmokers: a double-blind, placebo-controlled trial. doi:10.1007\/s00213-006-0516-y.","DOI":"10.1007\/s00213-006-0516-y"},{"key":"10.1016\/j.addr.2023.114824_b0615","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1007\/s10803-015-2471-0","article-title":"Reduction of Aggressive Episodes After Repeated Transdermal Nicotine Administration in a Hospitalized Adolescent with Autism Spectrum Disorder","volume":"45","author":"van Schalkwyk","year":"2015","journal-title":"J Autism Dev Disord"},{"key":"10.1016\/j.addr.2023.114824_b0620","doi-asserted-by":"crossref","first-page":"742","DOI":"10.2146\/ajhp180064","article-title":"Reduction of anxiety after treatment with transdermal clonidine","volume":"75","author":"Ye","year":"2018","journal-title":"American Journal of Health-System Pharmacy"},{"key":"10.1016\/j.addr.2023.114824_b0625","first-page":"110","article-title":"Clonidine as a Treatment of Behavioural Disturbances in Autism Spectrum Disorder: A Systematic Literature Review","volume":"29","author":"Banas","year":"2020","journal-title":"Journal of the Canadian Academy of Child and Adolescent Psychiatry"},{"key":"10.1016\/j.addr.2023.114824_b0630","author":"Carrithers","year":"2020","journal-title":"Transdermal Asenapine in Schizophrenia: A Systematic Review."},{"key":"10.1016\/j.addr.2023.114824_b0635","first-page":"60","article-title":"Asenapine Transdermal Patch for the Management of Schizophrenia","volume":"50","author":"Zhou","year":"2020","journal-title":"Psychopharmacol Bull"},{"key":"10.1016\/j.addr.2023.114824_b0640","doi-asserted-by":"crossref","unstructured":"Citrome, L., Courtney, ;, Zeni, M. & Correll, C. U. Expert Commentary Patches: Established and Emerging Transdermal Treatments in Psychiatry. (2019) doi:10.4088\/JCP.18nr12554.","DOI":"10.4088\/JCP.18nr12554"},{"key":"10.1016\/j.addr.2023.114824_b0645","unstructured":"Opinion: An Alternative to Injection. https:\/\/www.the-scientist.com (1986)."},{"key":"10.1016\/j.addr.2023.114824_b0650","doi-asserted-by":"crossref","first-page":"7760","DOI":"10.1128\/JVI.01849-09","article-title":"Intradermal Vaccination with Influenza Virus-Like Particles by Using Microneedles Induces Protection Superior to That with Intramuscular Immunization","volume":"84","author":"Quan","year":"2010","journal-title":"J Virol"},{"key":"10.1016\/j.addr.2023.114824_b0655","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jconrel.2016.01.019","article-title":"Induction of broad immunity by thermostabilised vaccines incorporated in dissolvable microneedles using novel fabrication methods","volume":"225","author":"Vrdoljak","year":"2016","journal-title":"Journal of Controlled Release"},{"key":"10.1016\/j.addr.2023.114824_b0660","doi-asserted-by":"crossref","unstructured":"Bhadale, R. S., Vaishali, \u00b7 & Londhe, Y. A comparison of dissolving microneedles and transdermal film with solid microneedles for iloperidone in vivo: a proof of concept. Naunyn Schmiedebergs Arch Pharmacol doi:10.1007\/s00210-022-02309-0.","DOI":"10.1007\/s00210-022-02309-0"},{"key":"10.1016\/j.addr.2023.114824_b0665","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.120007","article-title":"Transdermal delivery of breakthrough therapeutics for the management of treatment-resistant and post-partum depression","volume":"591","author":"Bhattaccharjee","year":"2020","journal-title":"Int J Pharm"},{"key":"10.1016\/j.addr.2023.114824_b0670","doi-asserted-by":"crossref","unstructured":"Lofts, A. et al. Using the Intranasal Route to Administer Drugs to Treat Neurological and Psychiatric Illnesses: Rationale, Successes, and Future Needs. CNS Drugs 2022 36:7 36, 739-770 (2022).","DOI":"10.1007\/s40263-022-00930-4"},{"key":"10.1016\/j.addr.2023.114824_b0675","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1016\/j.drudis.2019.06.001","article-title":"Antidepressants and nose-to-brain delivery: drivers, restraints, opportunities and challenges","volume":"24","author":"Vitorino","year":"2019","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.addr.2023.114824_b0680","first-page":"4316","article-title":"Can intranasal oxytocin reduce craving in automated addictive behaviours?","volume":"178","author":"Houghton","year":"2021","journal-title":"A systematic review. Br J Pharmacol"},{"key":"10.1016\/j.addr.2023.114824_b0685","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.neubiorev.2020.12.028","article-title":"Intranasal oxytocin in the treatment of autism spectrum disorders: A multilevel meta-analysis","volume":"122","author":"Huang","year":"2021","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.addr.2023.114824_b0690","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.psyneuen.2013.11.018","article-title":"Intranasal oxytocin as strategy for medication-enhanced psychotherapy of PTSD: Salience processing and fear inhibition processes","volume":"40","author":"Koch","year":"2014","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.addr.2023.114824_b0695","first-page":"1520","article-title":"Intranasal Ketamine for Depression in Adults: A Systematic Review and Meta-Analysis of Randomized, Double-Blind","volume":"12","author":"An","year":"2021","journal-title":"Placebo-Controlled Trials. Front Psychol"},{"key":"10.1016\/j.addr.2023.114824_b0700","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jpsychires.2020.12.038","article-title":"The acute antisuicidal effects of single-dose intravenous ketamine and intranasal esketamine in individuals with major depression and bipolar disorders: A systematic review and meta-analysis","volume":"134","author":"Xiong","year":"2021","journal-title":"J Psychiatr Res"},{"key":"10.1016\/j.addr.2023.114824_b0705","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jad.2020.01.002","article-title":"Adjunctive intranasal esketamine for major depressive disorder: A systematic review of randomized double-blind controlled-placebo studies","volume":"265","author":"Zheng","year":"2020","journal-title":"J Affect Disord"},{"key":"10.1016\/j.addr.2023.114824_b0710","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbr.2021.113611","article-title":"The activation of D2-like receptors by intranasal dopamine facilitates the extinction of contextual fear and prevents conditioned fear-induced antinociception","volume":"417","author":"de Almeida Silva","year":"2022","journal-title":"Behavioural Brain Research"},{"key":"10.1016\/j.addr.2023.114824_b0715","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13041-020-00649-7","article-title":"Altered dopaminergic pathways and therapeutic effects of intranasal dopamine in two distinct mouse models of autism","volume":"13","author":"Chao","year":"2020","journal-title":"Mol Brain"},{"key":"10.1016\/j.addr.2023.114824_b0720","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1093\/ijnp\/pyaa054","article-title":"A Randomized Controlled Trial of Intranasal Neuropeptide Y in Patients With Major Depressive Disorder","volume":"23","author":"Math\u00e9","year":"2020","journal-title":"International Journal of Neuropsychopharmacology"},{"key":"10.1016\/j.addr.2023.114824_b0725","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/nyas.14172","article-title":"Preclinical findings on the potential of intranasal neuropeptide Y for treating hyperarousal features of PTSD","volume":"1455","author":"Nwokafor","year":"2019","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.addr.2023.114824_b0730","doi-asserted-by":"crossref","unstructured":"Nahvi, R. J. & Sabban, E. L. Sex Differences in the Neuropeptide Y System and Implications for Stress Related Disorders. Biomolecules 2020, Vol. 10, Page 1248 10, 1248 (2020).","DOI":"10.3390\/biom10091248"},{"key":"10.1016\/j.addr.2023.114824_b0735","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics11030129","article-title":"Challenges and Recent Progress in Oral Drug Delivery Systems for Biopharmaceuticals","volume":"11","author":"Homayun","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.addr.2023.114824_b0740","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.cocis.2012.02.001","article-title":"Penetration of drugs through skin, a complex rate-controlling membrane","volume":"17","author":"Bolzinger","year":"2012","journal-title":"Curr Opin Colloid Interface Sci"},{"key":"10.1016\/j.addr.2023.114824_b0745","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cocis.2020.02.001","article-title":"Hydrogel design strategies for drug delivery","volume":"48","author":"Dreiss","year":"2020","journal-title":"Curr Opin Colloid Interface Sci"},{"key":"10.1016\/j.addr.2023.114824_b0750","unstructured":"Velligan, D. I. et al. The Expert Consensus Guideline Series: Adherence Problems in Patients with Serious and Persistent Mental Illness Editors for the Guidelines. (2009)."},{"key":"10.1016\/j.addr.2023.114824_b0755","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.phrs.2008.10.002","article-title":"The future (or lack of future) of personalized prescription in psychiatry","volume":"59","author":"de Leon","year":"2009","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.addr.2023.114824_b0760","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ejpb.2020.04.011","article-title":"QbD-driven development of intranasal lipid nanoparticles for depression treatment","volume":"153","author":"Vitorino","year":"2020","journal-title":"European Journal of Pharmaceutics and Biopharmaceutics"},{"key":"10.1016\/j.addr.2023.114824_b0765","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jconrel.2017.03.396","article-title":"Development of in vitro-in vivo correlation of parenteral naltrexone loaded polymeric microspheres","volume":"255","author":"Andhariya","year":"2017","journal-title":"Journal of Controlled Release"},{"key":"10.1016\/j.addr.2023.114824_b0770","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.jconrel.2020.06.023","article-title":"Continuous in-line homogenization process for scale-up production of naltrexone-loaded PLGA microparticles","volume":"325","author":"Sharifi","year":"2020","journal-title":"Journal of Controlled Release"},{"key":"10.1016\/j.addr.2023.114824_b0775","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1007\/s13346-021-01099-x","article-title":"Long-lasting rescue of schizophrenia-relevant cognitive impairments via risperidone-loaded microPlates","volume":"12","author":"Bellotti","year":"2022","journal-title":"Drug Deliv Transl Res"},{"key":"10.1016\/j.addr.2023.114824_b0780","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00289-013-1043-8","article-title":"Controlled release of highly water-soluble antidepressant from hybrid copolymer poly vinyl alcohol hydrogels","volume":"71","author":"Ali","year":"2014","journal-title":"Polymer Bulletin"},{"key":"10.1016\/j.addr.2023.114824_b0785","doi-asserted-by":"crossref","unstructured":"Kumar Satapathy, M. et al. pharmaceutics Solid Lipid Nanoparticles (SLNs): An Advanced Drug Delivery System Targeting Brain through BBB. (2021) doi:10.3390\/pharmaceutics13081183.","DOI":"10.3390\/pharmaceutics13081183"},{"key":"10.1016\/j.addr.2023.114824_b0790","doi-asserted-by":"crossref","unstructured":"Pinheiro, R. G. R., Coutinho, A. J., Pinheiro, M. & Neves, A. R. Molecular Sciences Nanoparticles for Targeted Brain Drug Delivery: What Do We Know? (2021) doi:10.3390\/ijms222111654.","DOI":"10.3390\/ijms222111654"},{"key":"10.1016\/j.addr.2023.114824_b0795","article-title":"Dendrimers in the context of targeting central nervous system disorders","volume":"73","author":"Palan","year":"2022","journal-title":"J Drug Deliv Sci Technol"},{"key":"10.1016\/j.addr.2023.114824_b0800","doi-asserted-by":"crossref","unstructured":"Bari, S. M. I., Hossain, F. B. & Nestorova, G. G. Advances in Biosensors Technology for Detection and Characterization of Extracellular Vesicles. Sensors 2021, Vol. 21, Page 7645 21, 7645 (2021).","DOI":"10.3390\/s21227645"},{"key":"10.1016\/j.addr.2023.114824_b0805","doi-asserted-by":"crossref","unstructured":"Zhou, L. et al. Targeted Drug Delivery to the Central Nervous System Using Extracellular Vesicles. Pharmaceuticals 2022, Vol. 15, Page 358 15, 358 (2022).","DOI":"10.3390\/ph15030358"},{"key":"10.1016\/j.addr.2023.114824_b0810","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.addr.2016.02.006","article-title":"Extracellular vesicles for drug delivery","volume":"106","author":"Vader","year":"2016","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.addr.2023.114824_b0815","doi-asserted-by":"crossref","unstructured":"Adepu, S. & Ramakrishna, S. Controlled drug delivery systems: Current status and future directions. Molecules vol. 26 Preprint at Doi: 10.3390\/molecules26195905 (2021).","DOI":"10.3390\/molecules26195905"},{"key":"10.1016\/j.addr.2023.114824_b0820","doi-asserted-by":"crossref","unstructured":"Sherje, A. P. & Londhe, V. Development and Evaluation of pH-Responsive Cyclodextrin-Based in situ Gel of Paliperidone for Intranasal Delivery. doi:10.1208\/s12249-017-0844-8.","DOI":"10.1208\/s12249-017-0844-8"},{"key":"10.1016\/j.addr.2023.114824_b0825","doi-asserted-by":"crossref","unstructured":"Agrawal, M. et al. Stimuli-responsive In situ gelling system for nose-to-brain drug delivery. Journal of Controlled Release vol. 327 235-265 Preprint at Doi: 10.1016\/j.jconrel.2020.07.044 (2020).","DOI":"10.1016\/j.jconrel.2020.07.044"},{"key":"10.1016\/j.addr.2023.114824_b0830","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120667","article-title":"Intranasal co-delivery of berberine and evodiamine by self-assembled thermosensitive in-situ hydrogels for improving depressive disorder","volume":"603","author":"Xu","year":"2021","journal-title":"Int J Pharm"},{"key":"10.1016\/j.addr.2023.114824_b0835","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/j.apsb.2021.01.014","article-title":"Intranasal temperature-sensitive hydrogels of cannabidiol inclusion complex for the treatment of post-traumatic stress disorder","volume":"11","author":"Pang","year":"2021","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.addr.2023.114824_b0840","doi-asserted-by":"crossref","DOI":"10.23893\/1307-2080.APS.05510","article-title":"Formulation And Characterization Of Intra Nasal Delivery Of Nortriptyline Hydrochloride Thermoreversible Gelling System In Treatment Of Depression","volume":"55","author":"Pathan","year":"2017","journal-title":"Acta Pharmaceutica Sciencia"},{"key":"10.1016\/j.addr.2023.114824_b0845","unstructured":"Xu, L. et al. Environmentally Responsive Multilayer Films Based on Block Copolymer Micelles and Natural Peptides for Controlled Release of Favipiravir."},{"key":"10.1016\/j.addr.2023.114824_b0850","doi-asserted-by":"crossref","first-page":"27665","DOI":"10.1039\/C5RA03535J","article-title":"Electroconductive smart polyacrylamide-polypyrrole (PAC-PPY) hydrogel: a device for controlled release of risperidone","volume":"5","author":"Saha","year":"2015","journal-title":"RSC Adv"},{"key":"10.1016\/j.addr.2023.114824_b0855","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/0168-3659(95)00134-4","article-title":"Pulsatile local delivery of thrombolytic and antithrombotic agents using poly(N-isopropylacrylamide-co-methacrylic acid) hydrogels","volume":"39","author":"Brazel","year":"1996","journal-title":"Journal of Controlled Release"},{"key":"10.1016\/j.addr.2023.114824_b0860","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/S1359-6446(05)03489-6","article-title":"Gastrointestinal patch systems for oral drug delivery","volume":"10","author":"Tao","year":"2005","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.addr.2023.114824_b0865","author":"Niwa","year":"2008","journal-title":"Preparation and Evaluation of a Time-Controlled Release Capsule Made of Ethylcellulose for Colon Delivery of Drugs."},{"key":"10.1016\/j.addr.2023.114824_b0870","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0168-3659(94)00131-D","article-title":"Pulsed FSH release from an implantable capsule system","volume":"34","author":"Ganiyu Jimoh","year":"1995","journal-title":"Journal of Controlled Release"},{"key":"10.1016\/j.addr.2023.114824_b0875","doi-asserted-by":"crossref","unstructured":"Santini, J. T., Richards, A. C., Scheidt, R., Cima, M. J. & Langer, R. Microchips as controlled drug-delivery devices. Angewandte Chemie - International Edition vol. 39 2396-2407 Preprint at Doi: 10.1002\/1521-3773(20000717)39:14<2396::AID-ANIE2396>3.0.CO;2-U (2000).","DOI":"10.1002\/1521-3773(20000717)39:14<2396::AID-ANIE2396>3.3.CO;2-L"},{"key":"10.1016\/j.addr.2023.114824_b0880","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1023\/A:1018960016756","article-title":"Programmable Drug Delivery from an Erodible Association Polymer System","volume":"10","author":"Xu","year":"1993","journal-title":"Pharmaceutical Research: An Official Journal of the American Association of Pharmaceutical Scientists"},{"key":"10.1016\/j.addr.2023.114824_b0885","author":"Raiche","year":"2003","journal-title":"Association polymers for modulated release of bioactive proteins."},{"key":"10.1016\/j.addr.2023.114824_b0890","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ijpharm.2007.03.007","article-title":"Bioerodible devices for intermittent release of simvastatin acid","volume":"340","author":"Jeon","year":"2007","journal-title":"Int J Pharm"},{"key":"10.1016\/j.addr.2023.114824_b0895","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1016\/j.biomaterials.2008.05.011","article-title":"Alternating Release of Different Bioactive Molecules from a Complexation Polymer System","volume":"29","author":"Jeon","year":"2008","journal-title":"Biomaterials"},{"key":"10.1016\/j.addr.2023.114824_b0900","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1080\/10837450802282488","article-title":"Formulations for intermittent release of parathyroid hormone (1\u201334) and local enhancement of osteoblast activities","volume":"13","author":"Jeon","year":"2008","journal-title":"Pharm Dev Technol"},{"key":"10.1016\/j.addr.2023.114824_b0905","doi-asserted-by":"crossref","DOI":"10.1002\/jbm.a.37497","article-title":"Interval delivery of 5HT2A agonists using multilayered polymer films","author":"Hossain","year":"2023","journal-title":"J Biomed Mater Res A"},{"key":"10.1016\/j.addr.2023.114824_b0910","unstructured":"View of Recent advances in 3D printing for floating drug delivery platforms. https:\/\/li01.tci-thaijo.org\/index.php\/sehs\/article\/view\/252666\/174599."},{"key":"10.1016\/j.addr.2023.114824_b0915","doi-asserted-by":"crossref","unstructured":"Reddy Dumpa, N., Bandari, S. & Repka, M. A. pharmaceutics Novel Gastroretentive Floating Pulsatile Drug Delivery System Produced via Hot-Melt Extrusion and Fused Deposition Modeling 3D Printing. doi:10.3390\/pharmaceutics12010052.","DOI":"10.3390\/pharmaceutics12010052"},{"key":"10.1016\/j.addr.2023.114824_b0920","unstructured":"ADHD Medication Manufacturing in the US - Market Size | IBISWorld. https:\/\/www.ibisworld.com\/industry-statistics\/market-size\/adhd-medication-manufacturing-united-states\/."},{"key":"10.1016\/j.addr.2023.114824_b0925","unstructured":"Antidepressant Drugs Market Size & Share, Forecast Report 2021-2027. https:\/\/www.gminsights.com\/industry-analysis\/antidepressant-drugs-market."}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X23001394?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X23001394?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T05:33:42Z","timestamp":1759210422000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X23001394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":185,"alternative-id":["S0169409X23001394"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2023.114824","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current and future directions of drug delivery for the treatment of mental illnesses","name":"articletitle","label":"Article Title"},{"value":"Advanced Drug Delivery Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addr.2023.114824","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"114824"}}